In 2019 Acorai was founded and set out to develop the first scalable and non-invasive intracardiac pressure monitor in the world.
Acorai believe that it has the potential to dramatically improve the health outcome for more than 60 million people suffering from heart failure around the world.
Press Release – January 2026 Life Science Invest’s sixth co-investment company, LSI Zeta, has raised EUR 2,9 million from 35 Nordic business angels with broad expertise in life science. The company will invest in around ten early-stage life science companies in the...
We are happy to introduce LSI Epsilons 9th investment Abarceo Pharma AB, a pre-clinical stage company, developing a platform for the treatment of mitochondrial diseases, with an initial focus on Type 2 Diabetes (T2D).We look forward to work closely with Adam Bruce,...
So excited to introduce our 8th investment. SampleFacts is reinventing blood 🩸 sampling by separating blood and plasma instantly. We look forward to work closely with Maryam Poorafshar, Kristina Svensson, Frida Ekholm, Ulf Landegren, Jon-Sverre Schanche and rest of...